HanchorBio Launches HCB101 Mechanism Collaboration Study with the Institute of Tsinghua University, Hebei
Research collaboration will investigate innate and adaptive immune pathways underlying the antitumor activity of HCB101
[Taipei, Shanghai, San Francisco | May 5, 2026] – HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced a research collaboration with the Institute of Tsinghua University, Hebei, to further characterize the antitumor mechanisms and translational biology of HCB101, the Company’s AI-guided, structurally engineered, Fc-based fusion protein targeting the CD47-SIRPα axis.
The collaboration is intended to deepen scientific understanding of the mechanisms and mode of action (MOA) underlying HCB101’s antitumor activity through focused in vivo studies spanning tumor immunity, immune cell function, antigen presentation, macrophage-mediated phagocytosis, downstream immune signaling, and hematologic biology. The work is expected to further strengthen the scientific foundation supporting the development of HCB101.
“Scientific depth matters,” said Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio. “As HCB101 continues to advance, we want to build not only clinical evidence, but also a stronger mechanistic understanding of how this molecule engages tumor cells while avoiding effects on normal blood cells. We chose to work with the Institute of Tsinghua University, Hebei, because of its strong research capabilities and the scientific rigor needed to investigate these complex questions in relevant translational models.”
Dr. Liu added, “At HanchorBio, we believe differentiated medicines are built on differentiated science. This collaboration is intended to help define the biology with greater precision, from innate immune activation and antigen presentation to downstream adaptive immune responses. Deep translational work like this can sharpen biomarker strategy, strengthen the combination rationale, and further clarify the broader therapeutic potential of HCB101 to support smarter development decisions as we expand the program.”
Professor Yangxin Fu, a senior expert in tumor immunology, noted that HCB101 represents an innovative molecule of significant scientific value for translational research. Built upon a differentiated CD47-SIRPα-targeting mechanism, HCB101 is closely aligned with key research directions in tumor immunity and effector-cell biology and carries important exploratory value for scientific investigation.
A research representative from the Institute of Tsinghua University, Hebei, commented: “The Institute looks forward to working closely with HanchorBio through a systematic and standardized research program to further investigate the mechanism of HCB101 across relevant experimental models. The project will focus on key dimensions including tumor immune regulation, immune signaling, antigen presentation, and effector-cell function, with the goal of helping research teams better clarify the regulatory logic of the CD47-SIRPα signaling pathway and its impact on antitumor immune responses, thereby strengthening the theoretical foundation for basic research and clinical translation in this field.”
The collaboration reflects HanchorBio’s broader approach of integrating clinical development with rigorous translational research to support next-generation immunotherapy programs.
About HCB101
HCB101 is a rationally engineered SIRPα–IgG4 Fc fusion protein developed using HanchorBio’s FBDB™ platform to selectively block the CD47–SIRPα innate immune checkpoint while minimizing hematologic toxicity. Unlike earlier anti-CD47 approaches, HCB101 is designed to preserve macrophage-mediated antitumor activity while reducing red blood cell binding, a limitation that historically constrained development across the CD47 class. HCB101 is being evaluated across multiple clinical settings as both monotherapy and combination therapy.
About the Institute of Tsinghua University, Hebei
The Institute of Tsinghua University, Hebei, was established in 2002 as a public institution jointly established by the Hebei Provincial People’s Government and Tsinghua University. With its headquarters in Shijiazhuang and additional bases in Langfang and Gu’an, the Institute is positioned around the coordinated development strategy of the Beijing-Tianjin-Hebei region and the development of Xiong’an New Area.
The Institute focuses on building a world-class new-type research and development institution by leveraging Hebei’s regional, industrial, and market advantages together with Tsinghua University’s innovation resources and organizational strengths. Its key areas of focus include carbon neutrality, life and health, intelligent equipment and electronic information technology, digital economy, and industrial design. The Institute aims to establish a full-chain innovation model spanning technology research and development, proof of concept, pilot-scale maturation, incubation, and translation, with the goal of becoming an influential regional integrated innovation center in China.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics intended to modulate innate and adaptive immune pathways with structural control over safety, exposure, and manufacturability. HanchorBio is advancing a portfolio of differentiated biologics designed to address significant unmet medical needs through innovative molecular engineering and scalable CMC strategies.